BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) on Tuesday agreed to acquire Astria Therapeutics, Inc. (NASDAQ:ATXS) for a mix of cash and stock.The deal represents an implied value of $13 per Astria share, and approximately$700 million in enterprise value.BioCryst will acquire all outstanding shares of Astria for consideration per share consisting of $8.55 in cash and 0.59 shares of BioCryst stock.Astria is a biopharmaceutical company focused on developing therapies for allergic and immunologic diseases.Also ...